Incyte Deal Further Validates Calithera Biosciences (CALA) Program - JMP

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ORCL
2. ANT
3. SPY
4. FFAI
5. FFR
6. META
7. FICO
8. CART
9. LLY
10. TSLA

Go back to Incyte Deal Further Validates Calithera Biosciences (CALA) Program - JMP

Incyte and Calithera Biosciences Announce Global Collaboration to Develop and Commercialize CB-1158, a First-in-class, Small Molecule Arginase Inhibitor

January 30, 2017 6:45 AM EST

Incyte gains worldwide rights to CB-1158 for hematology and oncology indications Calithera to receive a $45 million up-front payment and an $8 million equity investment Incyte and Calithera to co-fund global development of CB-1158; Calithera eligible to receive share of profits in the U.S., potential milestones and royalties on future sales of CB-1158  Calithera conference call scheduled today at 8:30 a.m. ET, 5:30 a.m. PT

WILMINGTON, Del. AND SOUTH SAN FRANCISCO, Calif., Jan. 30, 2017 (GLOBE NEWSWIRE) -- Incyte Corporation (NASDAQ: INCY) and Calithera... More